EUVIMEDEUVIMED entdecken
Fallbericht

Case report: a man with a pancreatic adenocarcinoma and negative CA 19-9, but positive CA 125

A. Müller, M. Franzoi, U. Enökl-Tomantschger, M. Pollheimer, K. Steidl, P. Hatzenbichler, H. Weiß, M. Tomka, H. Gröchenig

Zeitschrift für Gastroenterologie · 01.05.2024 · 62 (05) · e493

DOI: 10.1055/s-0044-1786920 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2024. Verfasst von A. Müller und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer is currently the third most common cause of cancer-related deaths. For a localized disease, surgery and adjuvant chemotherapy can be performed. Patients at an advanced stage, require target focused therapies with higher efficacy. According to the S3 guidelines, the analysis of only one tumor marker is recommended when a non-cystic pancreatic mass is detected: CA 19-9. Case report: We report a case of a 46-year-old man with metastatic adenocarcinoma of the pancreas shown on a diagnostic CT scan because of diffuse abdominal discomfort. The tumor marker revealed a negative CA 19-9. After histological confirmation the patient underwent three lines of chemotherapy (Gemcitabine/Paclitaxel, Folfirinox, 5-Fluorouracile and liposomal irinotecan). Due to fast tumor progression and a significantly reduced general condition, a planned 4 th line therapy with Olaparib was never initiated. Because of the progressive worsening of the general condition, the patient was admitted to hospital. On the day of admission the tumor marker was controlled again. Unintentionally, CA 125 was added to the routine tests, showing a markably elevated value up to 3190 U/ml. The patient passed away few weeks after the hospital admission. The subsequent immunohistochemistry of the initially taken biopsies confirmed CA 125 positivity in the pancreatic cells examined, with no reactivity of antibodies against CA 19-9.

Methods

We conducted a review of the current literature on PubMed with keywords “tumor markers in pancreatic cancer”, “CA 19-9, CA 125”, “tumor markers of pancreas”.

Conclusion

A review of the current literature indicates that CA 125 could be associated with tumor progression, metastasis and poor survival of patients with adenocarcinoma of the pancreas. Additionally, CA 125 might be a possible independent prognostic marker for postoperative pancreatic cancer. In a patient with pancreatic cancer and negative CA 19-9, CA 125 could be measured pointing to worse outcomes, as in our patient, who had a massive tumor progression under ongoing chemotherapy. Additionally ongoing research are indicating the positivity of CA 125 as future therapeutic target. Publication History Article published online: 05 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Müller, A., Franzoi, M., Enökl-Tomantschger, U., Pollheimer, M., Steidl, K., Hatzenbichler, P., Weiß, H., Tomka, M., & Gröchenig, H. (2024). Case report: a man with a pancreatic adenocarcinoma and negative CA 19-9, but positive CA 125. Zeitschrift für Gastroenterologie, 62(05), e493. https://doi.org/10.1055/s-0044-1786920

Vancouver

Müller A, Franzoi M, Enökl-Tomantschger U, Pollheimer M, Steidl K, Hatzenbichler P, et al. Case report: a man with a pancreatic adenocarcinoma and negative CA 19-9, but positive CA 125. Zeitschrift für Gastroenterologie. 2024;62(05):e493. doi:10.1055/s-0044-1786920

BibTeX
@article{Mller2024,
  author = {Müller, A. and Franzoi, M. and Enökl-Tomantschger, U. and Pollheimer, M. and Steidl, K. and Hatzenbichler, P. and Weiß, H. and Tomka, M. and Gröchenig, H.},
  title = {Case report: a man with a pancreatic adenocarcinoma and negative CA 19-9, but positive CA 125},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {05},
  pages = {e493},
  doi = {10.1055/s-0044-1786920}
}
Kostenlos starten →